PMID- 38020053
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20231201
IS  - 2352-9067 (Print)
IS  - 2352-9067 (Electronic)
IS  - 2352-9067 (Linking)
VI  - 49
DP  - 2023 Dec
TI  - Conduction system pacing for ventricular pacing requirement is feasible and 
      effective on patients with hypertrophic cardiomyopathy and cardiac dysfunction.
PG  - 101296
LID - 10.1016/j.ijcha.2023.101296 [doi]
LID - 101296
AB  - OBJECTIVE: We aimed to evaluate the feasibility and safety of his-bundle pacing 
      (HBP) and left bundle branch pacing (LBBP) in patients with hypertrophic 
      cardiomyopathy (HCM) and heart failure (HF). METHODS: Patients with HF and 
      interventricular septal thickness (IVST) >/= 13 mm resulted from HCM, who accepted 
      conduction system pacing (CSP) with a percentage of ventricular pacing > 40% from 
      May 2018 to April 2022 were consecutively enrolled in our center. LBBP was 
      preferred and HBP was the alternative therapy unless IVST >/= 16 mm or LBBP failed, 
      whereas LBBP would be the alternative therapy if HBP failed in patients with 
      IVST >/= 16 mm. All patients were followed up for at least one year. Data including 
      clinical, echocardiographic parameters and electrocardiogram measurements, were 
      collected and evaluated in patients with and without left ventricular ejection 
      fraction (LVEF) < 50%. RESULTS: A total of 27 patients (65.93 +/- 9.09 years old) 
      were enrolled and only 3 patients failed in CSP (11.11%) via LBBP (6/13) and HBP 
      (18/21) procedures. LVEF (P = 0.521), left ventricular end-diastolic diameter 
      (LVEDD) (P = 0.816), and QRS duration (P = 0.928) did not worsen after CSP, and 
      left atrial diameter (LAD) (49.58 +/- 8.99 mm vs.47.04 +/- 9.82 mm, P = 0.045) tended 
      to improve slightly after 19.19 +/- 7.71 months follow-up. Of note, LVEF 
      (39.22%+/-7.51% vs. 45.22%+/-9.59%, P = 0.015), LVEDD (52.11 +/- 10.10 mm vs. 
      48.33 +/- 9.07 mm, P = 0.037), LAD (50.33 +/- 8.93 mm vs. 46.11 +/- 5.97 mm, P = 0.013) 
      and New York Heart Association (NYHA) grade (2.67 +/- 0.5 vs. 1.38 +/- 1.02, 
      P = 0.029) improved in 9 patients with LVEF < 50%, whereas LVEF (P = 0.372), 
      LVEDD (P = 0.665), LAD (P = 0.093) and NYHA grade (P = 0.452) did not deteriorate 
      in patients with preserved ejection fraction. CONCLUSION: CSP was safe and 
      feasible in patients with HCM and cardiac dysfunction, and did not worsen cardiac 
      performance especially in patients with LVEF < 50%. HBP might be an effective 
      alternative to LBBP in patients with significantly thickened interventricular 
      septum.
CI  - (c) 2023 The Authors.
FAU - Jing-Jing, Jia
AU  - Jing-Jing J
AD  - Department of Cardiology, First Affiliated Hospital of Dalian Medical University, 
      Dalian, China.
FAU - Ke-Xin, Wang
AU  - Ke-Xin W
AD  - Department of Cardiology, First Affiliated Hospital of Dalian Medical University, 
      Dalian, China.
FAU - Zhao-Meng, Jing
AU  - Zhao-Meng J
AD  - Department of Cardiology, First Affiliated Hospital of Dalian Medical University, 
      Dalian, China.
FAU - Nan, Wang
AU  - Nan W
AD  - Department of Cardiology, First Affiliated Hospital of Dalian Medical University, 
      Dalian, China.
FAU - Lian-Jun, Gao
AU  - Lian-Jun G
AD  - Department of Cardiology, First Affiliated Hospital of Dalian Medical University, 
      Dalian, China.
FAU - Yun-Long, Xia
AU  - Yun-Long X
AD  - Department of Cardiology, First Affiliated Hospital of Dalian Medical University, 
      Dalian, China.
FAU - Ying-Xue, Dong
AU  - Ying-Xue D
AD  - Department of Cardiology, First Affiliated Hospital of Dalian Medical University, 
      Dalian, China.
LA  - eng
PT  - Journal Article
DEP - 20231107
PL  - Ireland
TA  - Int J Cardiol Heart Vasc
JT  - International journal of cardiology. Heart & vasculature
JID - 101649525
PMC - PMC10654017
OTO - NOTNLM
OT  - Conduction system pacing
OT  - Heart failure
OT  - His bundle pacing
OT  - Hypertrophic cardiomyopathy
OT  - Left bundle branch pacing
COIS- The authors declare that they have no known competing financial interests or 
      personal relationships that could have appeared to influence the work reported in 
      this paper.
EDAT- 2023/11/29 18:42
MHDA- 2023/11/29 18:43
PMCR- 2023/11/07
CRDT- 2023/11/29 14:38
PHST- 2023/08/28 00:00 [received]
PHST- 2023/10/26 00:00 [revised]
PHST- 2023/11/03 00:00 [accepted]
PHST- 2023/11/29 18:43 [medline]
PHST- 2023/11/29 18:42 [pubmed]
PHST- 2023/11/29 14:38 [entrez]
PHST- 2023/11/07 00:00 [pmc-release]
AID - S2352-9067(23)00127-6 [pii]
AID - 101296 [pii]
AID - 10.1016/j.ijcha.2023.101296 [doi]
PST - epublish
SO  - Int J Cardiol Heart Vasc. 2023 Nov 7;49:101296. doi: 10.1016/j.ijcha.2023.101296. 
      eCollection 2023 Dec.